Clinical evaluation of CG - 120 (Uralyt -U):The combined effect with uricosuric agent; Benzbromarone preparation

概要

論文の詳細を見る
After 135 patients with gout or asymptomatic hyperuricemia were divided into group A (84 patients) taking both CG - 120 and Benzbromarone, a uricosuric agent, and group B (51 patients) taking Benzbromarone alone, the combined effects of CG - 120and Benzbromarone on their clinical courses were observed for a period of 24 weeks, and the following findings were obtained. 1) Since urinary pH in group A was significantly higher than that in group B, CG -120 was proved highly effective in urine alkalization. 2) However, CG - 120 was not effective in the excretion of uric acid, since no significant difference was noted between the two groups in the serum uric acid, excretion of urinary uric acid or uric acid clearance. 3) Although no significant difference was recognized between the two groups in creatinine clearance or urine - concentrating capacity, the incidence of albumiuria and hematuria in group A was appreciably lower than that in group B for the period. 4) No significant difference was recognized between the two groups in the incidence of side effects and abnormal laboratory test results. Nonetheless, the medication was discontinued due to hematuria, hepatic disturbances, a decline of urinary pH, etc. in 4 patients in group B, but was discontinued in none of the patients group A. 5) From the above mentioned findings, it was concluded that combined use of CG -120 and Benzbromarone was considered superior to the use of Benzbromarone alone in treating patients with gout or asymptomatic hyperuricemia.
Japanese Society of Gout and Nucleic Acid Metabolismの論文

Clinical evaluation of CG - 120 (Uralyt -U):The combined effect with uricosuric agent; Benzbromarone preparation

スポンサーリンク

概要

著者

関連論文

スポンサーリンク